Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
April 28 2016 - 11:46AM
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a
specialty pharmaceutical company that develops and
markets solutions for the treatment of dermatological
conditions and advanced tissue care, today announced that Jim
Schutz, the company’s CEO, will present a corporate overview and
business update at the Third Annual Growth Capital Expo MicroCap
Investor Conference, to be held on May 3-5, 2016 at Caesars
Palace in Las Vegas. The Oculus presentation is scheduled on
Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to
immediately follow.
For those interested in attending the Oculus presentation,
registration is still open at
www.growthcapitalexpo.com/register-2/.
About the Growth Capital ConferenceThe Growth
Capital Expo is the premier conference for
emerging growth company
finance featuring:
- Presentations by selected MicroCap and
pre-IPO growth company management teams
showcasing the best opportunities of the year for emerging growth
investment.
- Two full days of educational panels and
presentations by the leading practitioners of investment
in public and late-stage private emerging growth
companies as well as a half-day educational pre-conference for
executive managers of pre-IPO and recently public companies.
About Oculus Innovative Sciences, Inc.Oculus
Innovative Sciences is a specialty pharmaceutical company that
develops and markets solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.oculusis.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Oculus Innovative
Sciences, Inc. and its subsidiaries (the “Company”). These
forward-looking statements are identified by the use of words such
as “present,” and “scheduled,” among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s common stock and warrants may be
delisted from NASDAQ, the Company’s products will not be
able to penetrate one or more targeted markets, revenues will
not be sufficient to fund further development and clinical studies,
the Company may not meet its future capital needs, the Company
may not be able to obtain additional funding, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K for
the year ended March 30, 2015. The Company disclaims any
obligation to update these forward-looking statements, except as
required by law.
Oculus® and Microcyn® Technology are trademarks or registered
trademarks of Oculus Innovative Sciences, Inc. All other trademarks
and service marks are the property of their respective owners.
Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024